Cinqair (Generic Reslizumab): Complete Medication Guide
Key Takeaways
Reslizumab is a monoclonal antibody used to treat moderate to severe eosinophilic asthma in adults and children.
It works by targeting and blocking interleukin-5 (IL-5), a protein that causes airway inflammation and eosinophil buildup.
Common side effects include upper respiratory tract infections, headache, and injection site reactions.
Serious side effects may include anaphylaxis, malignancy risk, and cardiovascular events requiring immediate medical attention.
Generic reslizumab offers the same effectiveness as brand-name Cinqair at a lower cost, making it an accessible treatment option.
Cinqair (Generic Reslizumab) Overview
Reslizumab is a monoclonal antibody medication designed to treat moderate to severe eosinophilic asthma in patients age 18 and older, with pediatric formulations available for children ages 12 and up. It belongs to a class of biologic drugs that specifically target the immune system's inflammatory pathways. This medication works by binding to interleukin-5 (IL-5), a protein that plays a central role in the development and activation of eosinophils—white blood cells that cause inflammation in the airways when overactive. By blocking IL-5, reslizumab significantly reduces airway inflammation, eosinophil buildup, and asthma symptoms in patients who haven't responded well to standard asthma treatments.
Eosinophilic asthma is a severe form of asthma characterized by abnormally high levels of eosinophils in the blood and airways. Patients with this condition typically experience frequent asthma attacks, difficulty breathing, and poor control with conventional inhalers or corticosteroids alone. Reslizumab is administered as an intravenous (IV) infusion, usually once every four weeks after an initial loading phase. Generic vs Brand Name Drugs share the same active ingredient and effectiveness, but generic versions cost significantly less, making this critical treatment more affordable for patients managing chronic asthma.
The development of reslizumab represents a major breakthrough for asthma patients who struggle with frequent exacerbations and hospitalizations. Clinical studies show that reslizumab can reduce asthma exacerbations by up to 60% in eligible patients, dramatically improving quality of life and reducing healthcare costs related to emergency visits and hospitalizations.
Side Effects
Reslizumab is generally well-tolerated by most patients, though like all biologic medications, it carries potential side effects ranging from mild to serious. Understanding these effects helps you recognize symptoms early and know when to contact your healthcare provider.
Common Side Effects
Upper respiratory tract infections (URIs): Infections affecting the nose, throat, and sinuses are among the most frequently reported side effects, occurring in 10-15% of patients.
Headache: Mild to moderate head pain occurs in approximately 8-12% of patients and typically resolves without intervention.
Injection site reactions: Redness, swelling, itching, or bruising at the IV infusion site may occur but usually resolve within a few hours.
Muscle and joint pain: Some patients experience myalgia or arthralgia, typically mild and manageable with over-the-counter pain relief.
Fatigue: General tiredness or weakness occurs in a small percentage of patients, usually improving after the first few doses.
Serious Side Effects
Anaphylaxis: A severe allergic reaction occurring during or shortly after infusion, marked by difficulty breathing, throat tightness, low blood pressure, and loss of consciousness requiring immediate emergency care.
Malignancy: Long-term immune suppression may increase the risk of certain cancers, particularly lymphoma, though this remains relatively rare.
Cardiovascular events: Including heart attack or stroke, though these are uncommon; patients with pre-existing heart disease face elevated risk.
Nervous system disorders: Rare cases of peripheral neuropathy, facial paralysis, or guillain-barré syndrome have been reported.
Severe infections: Reslizumab may increase susceptibility to serious infections, including tuberculosis, histoplasmosis, or pneumocystis pneumonia in immunocompromised patients.
When to Seek Medical Attention
Contact your doctor immediately if you experience difficulty breathing, chest pain, severe swelling, persistent fever, or signs of infection during or after receiving reslizumab. Additionally, seek prompt medical care if you notice unusual bleeding or bruising, severe headache with vision changes, muscle weakness, or any symptoms suggesting an allergic reaction. While most side effects resolve independently, immediate professional evaluation ensures serious complications are identified and managed quickly to prevent complications.
Dosage
Dose Level or Form |
Dose |
Key Detail |
Loading Phase |
3.75 mg/kg IV infusion |
Given at weeks 0, 2, and 4; may be combined into a single infusion depending on clinical judgment |
Maintenance Phase |
3.75 mg/kg IV infusion |
Administered once every four weeks for ongoing disease control |
Infusion Duration |
45-90 minutes |
Given intravenously over this time period with medical supervision |
Typical Body Weight Dosing |
150-200 lbs: 250-300 mg per dose |
Weight-based calculations ensure appropriate therapeutic levels |
Pediatric Dosing |
Same weight-based formula |
Ages 12+; dosing remains consistent across age groups once weight threshold met |
Important: Never skip scheduled infusions or stop reslizumab without discussing with your doctor, as sudden discontinuation may worsen asthma control and increase exacerbation risk. If you miss an infusion appointment, contact your healthcare provider immediately to reschedule; delaying doses beyond four weeks may reduce medication effectiveness. Always inform all medical providers that you're receiving reslizumab, particularly before undergoing surgery or receiving live vaccines, which are contraindicated during treatment.
Drug Interactions
Reslizumab has fewer direct drug-drug interactions compared to many medications because it works through the immune system rather than being metabolized by the liver. However, certain medications and vaccines can affect its safety and efficacy.
Live Vaccines
Live vaccines (including MMR, varicella, and yellow fever) should not be administered during reslizumab treatment due to immunosuppression increasing infection risk from attenuated organisms.
Other Biologic Asthma Medications
Combining reslizumab with other biologic asthma drugs (omalizumab, mepolizumab, benralizumab) is not recommended without specialist oversight, as combination therapy may increase immunosuppression and infection risk.
Immunosuppressive Drugs
Concurrent use with corticosteroids, azathioprine, or other immunosuppressants may compound infection risk and reduce immune function, requiring close medical monitoring.
Antifungal and Antimycobacterial Medications
Medications treating serious infections like tuberculosis or fungal infections should be carefully coordinated with reslizumab therapy, as immune suppression complicates infection control.
Non-Live Vaccines
Inactivated vaccines (flu, pneumococcal, COVID-19) may have reduced effectiveness during reslizumab treatment but should still be administered as recommended, ideally before starting therapy.
Continue Learning
Related articles you might find helpful
Pros and Cons
Pros
Dramatically reduces asthma exacerbations by up to 60% in eligible patients with eosinophilic asthma
Targets the specific immune pathway driving eosinophilic inflammation, offering precision medicine benefits
Significantly improves quality of life and reduces emergency room visits and hospitalizations
Cost-effective alternative to brand-name drugs makes biologic therapy more accessible to patients
Once-monthly maintenance infusions reduce treatment burden compared to daily medications
Cons
Requires IV infusion in a healthcare facility, limiting convenience compared to oral or inhaled medications
Higher upfront cost than standard asthma controller inhalers, though generic versions are more affordable
Significant infection risk requires ongoing monitoring and TB screening before and during treatment
Not suitable for patients with active infections, tuberculosis, or severe immunosuppression
Potential malignancy risk with long-term use remains a concern for some patients requiring risk-benefit discussion
Frequently Asked Questions
Get answers to common questions about Cinqair (Generic Reslizumab).
Generic reslizumab contains the identical active ingredient and delivers the same therapeutic benefit as brand-name Cinqair. Generic vs. Brand-Name Drugs are equally effective and safe according to FDA standards. The primary difference is cost—generic versions typically cost 20-50% less, making treatment more affordable without sacrificing quality or outcomes.
Most patients notice meaningful improvement in asthma symptoms within 2-4 weeks of starting treatment, with maximal benefit typically achieved by 8-12 weeks. The loading phase during weeks 0-4 helps build therapeutic levels quickly. Some patients experience symptom improvement even sooner, while others may require the full 12-week period to realize full benefit. Patience and consistent adherence to the infusion schedule are essential.
Reslizumab can be used alongside conventional asthma medications like inhaled corticosteroids and bronchodilators, and many patients continue these treatments. However, combining reslizumab with other biologic asthma medications (mepolizumab, omalizumab, benralizumab) is generally not recommended without specialist oversight. Your pulmonologist will optimize your complete medication regimen based on your specific asthma severity and response to treatment.
Contact your healthcare provider immediately to reschedule your missed infusion. The goal is to maintain a regular four-week infusion schedule for consistent disease control. Missing doses may reduce medication effectiveness and increase asthma exacerbation risk. Your provider can adjust the schedule if necessary, but delaying beyond four weeks should be minimized to maintain optimal therapeutic benefit and control.
Reslizumab is approved for children ages 12 and older with moderate to severe eosinophilic asthma, using the same weight-based dosing as adults. Safety and efficacy in pediatric patients were established through clinical trials, showing similar side effect profiles and benefits. Children must still undergo TB screening and other pre-treatment evaluations. Your pediatric pulmonologist will determine if reslizumab is appropriate for your child's specific condition.
The Bottom Line
Reslizumab is a powerful biologic medication offering significant benefits for patients with moderate to severe eosinophilic asthma who haven't achieved adequate control with standard treatments. By targeting the IL-5 immune pathway, it reduces inflammation, exacerbations, and hospitalizations dramatically—often by 50-60% in eligible patients. Generic reslizumab provides this same life-changing therapy at a lower cost than brand-name Cinqair. However, it requires careful monitoring for infections, regular IV infusions, and evaluation for serious side effects. The decision to start reslizumab should involve thorough discussion with your pulmonologist about your asthma severity, infection risk, and treatment goals. This information is educational and does not replace advice from your healthcare provider.
Ready to take control of your health? Save money on generic drugs for high blood pressure and cholesterol by exploring affordable biologic options with Doctronic. Get a free AI consultation today—Doctronic is the first AI legally authorized to practice medicine and has completed over 22 million consultations with 99.2% treatment alignment with physicians. Available 24/7 with just a 4-minute wait for personalized guidance on your asthma treatment plan.
